stocktitan.netSEP 141 min read$RYTM

Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM)

Rhythm Pharmaceuticals (RYTM) insider David Meeker filed a Rule 144 notice to sell 50,000 shares, valued at $5.24M, acquired via option exercise on or after September 14, 2026, through Morgan Stanley.

Original reporting

stocktitan.net

Published Sep 14, 2026, 8:56 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 8:30 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$RYTM

Bearish

medium confidence

Mentioned

$RYTM

Relevance

5/10

AlphAI data visualization · based on stocktitan.net

Decision brief

The 30-second read

$RYTMBearishLow

Why it matters

The disclosed sale represents a $5.2M transaction, which is sizable for Rhythm Pharmaceuticals and may influence short‑term price action.

Market read

First‑report insider sale; modest materiality; likely short‑term price impact.

What to watch

Potential upcoming catalyst (e.g., trial data) could offset selling pressure.

Relevance 5/10Novelty 5/10Timing: filing effective on or after Sep 14, 2026

Background

Rule 144 allows insiders to sell restricted shares after a holding period; filings are public and often tracked by traders.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RYTMBearishMedium confidence

Context

David Meeker filed a Rule 144 notice to sell 50,000 Rhythm Pharmaceuticals shares worth $5.2M.

Expected impact

Modest dip in RYTM price over the next few days.

Evidence & confidence

Insider sales often signal lack of confidence; the $5.2M size is material for a micro‑cap.

Market effects

Sector

Minimal impact on broader biotech sector.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

Insider
David Meeker
Officer/director filing the Rule 144 sale.
Broker
Morgan Stanley Smith Barney LLC
Broker handling the transaction.

Read at source ← All news

SEP 14

$RYTMMedAI 8/10

Does New Childhood Obesity Data Change The Bull Case For Rhythm Pharmaceuticals (RYTM)?

Rhythm Pharmaceuticals (RYTM) presented new data at the 64th ESPE Meeting, showing positive results for setmelanotide in treating paediatric acquired hypothalamic obesity, including BMI reductions and improved metabolic indices. Analysts note this strengthens the company's clinical story but does not alter its near-term financial losses. The data may support future regulatory and reimbursement progress, with analysts projecting significant revenue growth by 2029.

simplywall.st3 min

SEP 14

$RYTMMed

Rhythm Pharmaceuticals assumed with an Outperform at Leerink

Leerink initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $133 price target, citing its leadership in rare obesity treatments and growth prospects.

tipranks.com1 min

SEP 10

$RYTMMedAI 8/10

French children showed lower body-size scores on a rare-obesity drug

Rhythm Pharmaceuticals (RYTM) presented data at ESPE 2026 showing setmelanotide reduced BMI and improved cardiometabolic markers in paediatric hypothalamic obesity patients. Real-world data from France showed mean BMI reductions of 11.5% at 6 months and 9.0% at 18 months. Phase 3 analyses showed significant improvements in metabolic indices compared to placebo.

stocktitan.net3 min

AUG 28

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

finanznachrichten.de3 min

AUG 26

$RYTMMed

Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Rhythm Pharmaceuticals (RYTM) received marketing approval in Japan for its drug IMCIVREE. The stock has gained 11% in the past month and 24% in 90 days. Analysts suggest the company may be 15% undervalued, with a fair value estimate of $134, but it trades at a high P/S ratio of 32.5x.

simplywall.st2 min

AUG 24

$RYTMHighAI 8/10

Rhythm Wins Japan Nod For IMCIVREE As First Treatment For Acquired Hypothalamic Obesity; Stock Up

Rhythm Pharmaceuticals (RYTM) received Japanese approval for IMCIVREE to treat acquired hypothalamic obesity, a rare condition. The approval follows a Phase 3 trial showing significant BMI reduction. Rhythm estimates 5,000-8,000 people in Japan have this condition. The UK also expanded IMCIVREE's authorization. RYTM stock is up 0.99% to $110 at close, down 0.72% in pre-market.

rttnews.com2 min